Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJ5DAB)

• Drug Name: esamisulpride Drug Info
• Synonyms: (S)-amisulpride; 71675-92-8; Amisulpride, (S)-; ES3TWM82E8; Benzamide, 4-amino-N-(((2S)-1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-; (S)-4-Amino-N-((1-ethylpyrrolidin-2-yl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; (S)-4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; UNII-ES3TWM82E8; S-Amisulpride; ESAMISULPRIDE; S-(-)-Amisulpride; ESAMISULPRIDE [INN]; SCHEMBL675545; NTJOBXMMWNYJFB-LBPRGKRZSA-N; DTXSID301316207; EX-A5710; AKOS040747622; 4-amino-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-5-ethylsulfonyl-2-methoxybenzamide; AC-37136; MS-25938; HY-126068; CS-0090362; Q27277333; (S)-(-)-N-(1-ethyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-ethylsulphonylbenzamide

Indication

Disease Entry	ICD 11	Status	REF
Bipolar disorder	6A60	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 3055076
  TTD Drug ID: DMJ5DAB

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[3]
Haloperidol	DM96SE0	Delirium		Approved	[4]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[5]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[6]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[7]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[8]
Quetiapine	DM1N62C	Anorexia nervosa cachexia	6B80	Approved	[9]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[10]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[11]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[2]

References

• [1] ClinicalTrials.gov (NCT05227209) A 12-Month Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression). U.S.National Institutes of Health.
• [2] Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders. Clin Pharmacol Ther. 2021 Sep;110(3):808-815.
• [3] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [4] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [5] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [6] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [7] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [9] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [10] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [11] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [12] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.